



3.4.9 Emergency and Critical Pathology Group



Publications:4 | Q1:4

COMPOSITION

Alejandro Martín Quirós.

Unidad de Aislamiento de Alto Nivel. Hospital Universitario La Paz

- **Gillermína Bejarano Redondo.** Médico Adjunto en Urgencias. Hospital Universitario La Paz
- **Lubna Dani Ben Abdel-lah.** Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz
- **María Elena Calvín García.** Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz
- **Julio Cobo Mora.** Jefe de la Unidad de Urgencias. Hospital Universitario La Paz
- **María de los Ángeles García Martín.** Facultativo Especialista de Área especialista en Farmacia Hospitalaria. Hospital Universitario La Paz

- **Olga González Peña.** Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Hospital Universitario La Paz
- **Manuel Jesús González Viñolis.** Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz
- **Macarena Lerín Baratas.** Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz
- **María Lorena López Corcuera.** Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz
- **Mikel Rico Briñas.** Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz
- **Paloma Isabel Romero Gallego-Acho.** Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz
- **María José Simón Merlo.** Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz

STRATEGIC OBJETIVES

- Our group will investigate new strategies to address very different pathologies that are presented in our emergency department, national referent in different fields of diagnosis and treatment. This heterogeneous group of specialists, will approach 6 main lines of research, which aim to contribute to the better definition of clinical, diagnostic and treatment strategies.
- We collaborate with other research groups, to study clinical and prognostic usefulness tests in cardiology, to develop new strategies for the treatment and diagnosis of infectious diseases, and to investigate new antibiotics with the pneumology group.
- We develop a new and pioneering line of imagingdiagnostic, with the line of emergency ultrasound, being national referents in research in this field, in which we have the active support of private enterprise.
- We will investigate the possibility of supporting us in new technologies that help the clinician in the decision making in the field of the treatment of the diabetes, impelling global initiatives both at the hospital and the population level.
- Finally, we will develop a line of toxicological research, focusing both on the early recognition of the intoxicated patient, as well as their adequate treatment, in collaboration with the clinical toxicology unit (CTU), with the aim of becoming a national reference center in the Management of the intoxicated patient, as well as in the development of protocols of attention to multiple victims of biological attack.



3. Information groups by area

3.4 Large System Pathologies Area

RESEARCH LINES

- Integral management of the treatment and follow-up of the diabetic patient.
- Emergency ultrasound.
- Sepsis
- SARS-CoV-2 and COVID19 acute management
- Care of infectious diseases in the emergency room.
- Optimization of the management of the acute intoxicated patient and use of chemical substances for terrorist purposes.
- Attention to cardiovascular pathology of emergencies.
- Attention to respiratory pathology.

RESEARCH ACTIVITY

Publications

- Gonzaga A, Andréu E, Hernández-Blasco LM, Meseguer R, Al-Akoui-Sanz K, Soria-Juan B, Sanjuán-Giménez JC, Ferreras C, Tejedo JR, López-Lluch G, Goterris R, Maciá L, Sempere-Ortells JM, Hmadcha A, Borobia A, Vicario JL, Bonora A, Aguilar-Gallardo C, Poveda JL, Arbona C, Alenda C, Tarín F, Marco FM, Merino E, Jaime F, Ferreres J, Figueira JC, Cañada-Illana C, Querol S, Guerreiro M, Eguizabal C, Martín-Quirós A, Robles-Marhuenda A, Pérez-Martínez A, Solano C, Soria B. Rationale for combined therapies in severe-to-critical COVID-19 patients. *Front Immunol.* 2023; 14: 1232472. Review. IF: 5.7; Q1
- Lozano-Rodríguez R, Avendaño-Ortiz J, Montalbán-Hernández K, Ruiz-Rodríguez JC, Ferrer R, Martín-Quirós A, Maroun-Eid C, González-López JJ, Fàbrega A, Terrón-Arcos V, Gutiérrez-Fernández M, Alonso-López E, Cubillos-Zapata C, Fernández-Velasco M, de Diego RP, Pelegrín P, García-Palenciano C, Cueto EJ, del Fresno C, López-Collazo E. The

prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsis. *Ebiomedicine.* 2023; 97: 104841. Article. IF: 9.7; D1

- Lozano-Rodríguez R, Avendaño-Ortiz J, Terrón V, Montalbán-Hernández K, Casalvilla-Dueñas J, Bergón-Gutiérrez M, Mata-Martínez P, Martín-Quirós A, García-Garrido MA, del Balzo-Castillo A, Peinado M, Gómez L, Llorente-Fernández I, Martín-Miguel G, Herrero-Benito C, López-Morejón L, Vela-Olmo C, Cubillos-Zapata C, López-Collazo E, del Fresno C. mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naive and COVID-19-recovered individuals. *Front Immunol.* 2023; 14: 1136029. Article. IF: 5.7; Q1
- Pascale R, Toschi A, Aslan AT, Massaro G, Maccaro A, Fabbriatore D, Dell'Aquila A, Ripa M, Isik ME, Kazmaz YU, Iacopino S, Camici M, Perna F, Akinosoglou K, Karruli A, Papadimitriou-Olivgeris M, Kayaaslan B, Bilir YA, Özcan EE, Turan OE, Isik MC, Pérez-Rodríguez MT, Yagüe BL, Quirós AM, Yilmaz M, Petersdorf S, De Potter T, Durante-Mangoni E, Akova M, Curnis A, Gibertoni D, Diemberger I, Scudeller L, Viale P, Giannella M. Risk factors for Gram-negative bacterial infection of cardiovascular implantable electronic devices: multicentre observational study (CarDINE Study). *Int J Antimicrob Ag.* 2023; 61(3): 106734. Article. IF: 4.9; Q1

Research projects

- Martín Quirós A. Impacto del retraso en el inicio de la antibióterapia e identificación de biomarcadores pronósticos en la evolución de pacientes con sepsis a shock séptico (PI20/01589). ISCIII. 2021-2023. *Managment centre: FIBHULP*

Clinical trials

- Martín Quirós A. Estudio de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de bemnifosbu-

vir en pacientes ambulatorios de alto riesgo con covid-19.

Type/Phase: III

Sponsored by: Atea Pharmaceuticals, Inc

Signed date: 04/07/2023

- Martín Quirós A. Estudio retrospectivo y descriptivo para describir la co-medificación basal que reciben los pacientes hospitalizados por covid-19 respiratorio en España. estudio cos.

Type/Phase: EPA-OD

Sponsored by: Merck Sharp And Dohme De España, S.A.

Signed date: 24/03/2023

